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The prevalence of asthma in children and adolescents continues to increase world-wide, with asthma remaining the 
most common chronic illness of childhood. Morbidity is high in the latter age group, indicating that many 
adolescents with asthma symptoms are not receiving appropriate treatment for their condition. 
Inadequate symptomatic control should alert the physician to the possibility of non-compliance, which is not 
limited to those patients with a poor understanding of their condition. Psychosocial problems, such as isolation and 
low self-esteem, are inherent in adolescents with asthma due, in part, to the highly visible nature of symptoms and 
the method of delivery of current inhaled therapy. Compliance with therapy in adolescents in particularly low if the 
dosing regimen is more than twice daily, with poor inhaler technique contributing to ineffective control. 
Failure to take asthma medication can result in asthma exacerbations and increased disease severity, with the 
resultant need for powerful medication and hospitalization (incurring substantial patient and healthcare costs). 
Although better management techniques, such as tailoring medication and individualizing treatment regimens may 
improve compliance in this group, there is an obvious need for alternative treatment options. 
An effective and well tolerated oral tablet therapy, with a simple unobtrusive regimen, would provide a potential 
solution to the high level of non-compliance seen in this age group. The leukotriene receptor antagonists offer a 
practical alternative amongst existing oral therapies, and their efficacy and simple oral dosing regimen may prove 
valuable in increasing compliance in adolescents. 
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Introduction 
The prevalence of asthma in children and adolescents 
continues to increase world-wide (I), with asthma remain- 
ing the most common chronic illness of childhood (2,3). In 
1996, the world-wide prevalence of wheeze, a predominant 
symptom of asthma, was reported in approximately 14% of 
13-14 year olds (4). In 1997, prevalence was reported to be 
higher, at 32%, in the U.K. with similar rates in the U.S. 
and New Zealand at 22% and 30%, respectively (2,5). 
Asthma in adolescents (defined by the World Health 
Organization as spanning the ages of 10-19 years) (6) is 
associated with higher mortality rates when compared with 
rates in younger children with asthma. For example, between 
1990 and 1992, the U.K. mortality rate due to asthma in 10- 
14 year olds was three times that of 5-9 year olds and the 
rate for 15-19 year olds was six times that of 5-9 year olds 
(7). Morbidity in this age group is also unacceptably high; 
almost all adolescents with asthma report that their 
symptoms interfere with daily activities such as lessons and 
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physical activity (2). In the U.S. poor control of asthma 
results in over 10 million missed school days per year (8). 
Whilst the prevalence of asthma in adolescents continues 
to rise, there are indications that many adolescents with 
asthma symptoms are not receiving treatment for their 
condition. In nearly 500 Danish adolescents aged 12-15 
years, 25% were recorded as having asthma-like symptoms 
and only 70% of these had been diagnosed with asthma (9). 
This was despite the presence of symptoms of cough, 
wheezing, dyspnoea and at least one positive test result for 
asthma. Similarly, in a U.K. study of nearly 28 000 12-14 
year olds, over 30% reported symptoms of wheeze, with 
only 50% having been diagnosed with asthma. Only 20% 
of the adolescents in this study had received drug treatment 
for wheezing and asthma in the past year (2). 
The high morbidity and mortality rates in adolescents with 
asthma indicate that underdiagnosis and under-treatment of 
this condition is a major problem in this age group (2). 
Psychosocial problems associated 
with adolescent asthma 
The need for asthma therapy, particularly when adminis- 
tered in a visible manner, identifies the adolescent with their 
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condition and can discriminate them from their peers. This 
can lead to isolation from peer interaction, sport and other 
activities. Adolescents are constantly striving to achieve 
independence from their parents, a process that is 
hampered by regular attendance at clinics, with the doctor 
discussing treatment with the parent and not the adoles- 
cent. 
Adolescents have a great need to be accepted by their 
peers and are dependent on them for approval of their 
behaviour. A recent survey in the U.K. showed that 10% of 
adolescents worry about the effect of asthma on personal 
relationships, and one in five adolescents do not like taking 
their asthma medication in front of others (10). Increased 
knowledge of asthma among healthy adolescents is 
associated with a more positive attitude towards, and a 
greater acceptance of those with asthma (11). 
Feelings- of isolation amongst adolescents with asthma 
may be compounded by delays in the physiological changes 
that occur during adolescence; 45% of children with 
asthma experience delays in the onset of puberty and tend 
to be smaller and less sexually mature than their peers (12). 
As treatment with inhaled corticosteroids has been asso- 
ciated with growth suppression (13), this knowledge may 
create a barrier to achieving full compliance with this type 
of therapy. 
Frequent absence from school and social activities may 
cause adolescents with asthma to suffer psychological 
disturbances of self-esteem and self-image. Moderate and 
severe persistent asthma appears to be associated with 
increased incidence of particular categories of psychiatric 
problems in children and adolescents, in particular inter- 
nalized anxiety disorders with anxious/depressive symp- 
toms (14). Feelings of helplessness, depression and hostility, 
seen particularly with severe asthma, may result in 
disregard for treatment (15). The risk of serious behaviour- 
al problems in adolescents with severe asthma is nearly 
three times that in young people who do not have asthma 
(16). 
The desire of adolescents to be accepted by their peers 
may lead to risk-taking behaviour. Adolescents with a past 
history of asthma show a stronger intention to become 
smokers than non-asthmatics and identify closely with the 
image of smokers (17). One theory for this is that these 
adolescents are making a statement that they are not 
threatened by the stigma of their disease and that they can 
smoke because they have healthy lungs. It appears that self- 
image is more important than health status when under- 
standing attitudes towards smoking. 
The possibility of having an asthma attack during 
exercise results in many adolescents withdrawing from 
physical activity. Studies have shown that 3040% of 
adolescents with asthma either have to stop in the middle or 
miss out on sports completely, with 77% of children with 
asthma aged 4-17 years having difficulty with certain sports 
(l&19). Missed sport, and days off school in general, cause 
added stress with more than one third of adolescents with 
asthma worrying that it will affect their future career 
options (10). 
It is clear that asthma causes particular problems in the 
adolescent age group. Psychosocial factors, including 
depression and poor interpersonal skills, are inherent in 
adolescents with asthma and have been shown to have an 
adverse impact on compliance with asthma therapy (20). In 
addition, the highly visible nature of asthma, the symptoms 
and the use of inhaled therapy, isolates the adolescent from 
their peers. This, possibly combined with concerns about 
side effects with inhaled corticosteroids, may lead to poor 
compliance. 
Non-compliance with inhaled asthma 
therapy 
In mild, intermittent asthma, short-acting beta-agonists are 
traditionally used alone as first-line therapy, with inhaled 
corticosteroids being prescribed with increasing disease 
severity. Compliance with inhaled medication is generally 
poor during the long-term treatment of asthma and 
incorrect inhaler use is common (21). In adults with mild- 
to-moderate asthma, compliance has been reported to be as 
high as 73% with an inhaled asthma medication prescribed 
three times daily. However, actual compliance as measured 
by canister weight change was much lower, with only 15% 
of adults using their inhaler an average of 2.5 or more times 
per day (22). Similarly, another study in patients aged 18- 
70 requiring treatment with regular inhaled steroids and 
beta-agonists, showed that only 14% of patients took the 
prescribed twice-daily dose of inhaled asthma medication 
on more than 80% of days (23). 
A medication required more than twice daily adds 
restraints to daily life, especially in adolescents, and may 
result in one or more missed doses (24). Incorrect dosing 
may lead to ineffective control of asthma symptoms, 
causing the adolescent to believe that treatment is not 
working and, therefore, not worth taking. In a study in 
children with asthma aged 8-12 years who required both 
inhaled corticosteroid and beta-agonist therapy, self- 
reported and electronically monitored compliance with 
inhaled corticosteroids were measured. More than 90% of 
children exaggerated their use of medication (25). The 
median reported use of inhaled corticosteroids was 95%, 
whereas the median actual use was 58%, demonstrating 
that actual compliance is much less than that reported by 
patients. The results also indicated a striking relationship 
between poor corticosteroid adherence and exacerbation of 
asthma (25). Evidently, asthma therapy needs to be 
consistent; however, the high level of non-compliance in 
this age group can lead to poor asthma control, a problem 
that needs to be addressed (25). 
There are concerns regarding impaired growth and 
incorrect association with anabolic steroids (26,27). There 
is no conclusive evidence to demonstrate any long-term 
systemic side effects associated with the use of inhaled 
corticosteroids. However, the concern about possible side 
effects, whether justified or not, can lead to poor 
compliance. The risk-benefit ratio of corticosteroids in 
paediatric asthma is acceptable, although the possibility of 
premature osteoporosis in patients with perhaps 30-40 
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years’ regular use cannot be excluded (28). In order to 
minimize the potential risk of high-dose corticosteroids, 
dosing should be kept at the minimum needed to achieve 
adequate asthma control. Non-corticosteroidal add-on 
therapy with a long-acting beta-agonist or a leukotriene 
receptor antagonist (LTRA) could be considered as an 
alternative to increasing the corticosteroid dose. A greater 
benefit from add-on therapy is normally seen compared 
with doubling the dose of inhaled corticosteroid (29-32). 
Implications for increased morbidity and mortality 
associated with poor compliance with asthma therapy in 
this age group emphasize the importance of treating 
adolescents as a separate and special group with individual 
needs (6). 
Finding a solution to the problem of 
non-compliance 
By tailoring medication to the adolescent, allowing them 
more control over their disease with a choice of alternative 
treatments, compliance in this group may be improved. A 
good approach is to build a partnership between doctor and 
adolescent, allowing discussion of management and treat- 
ment options (33). Educating parents to allow the 
adolescent control over decisions is essential, although the 
parent will have an important role in reinforcing the belief 
that treatment is safe and effective. The treatment guide- 
lines available should be used flexibly and should be 
individualized to suit the lifestyle of the adolescent, not the 
parent (34). An approach involving discussing healthy 
lifestyle, rather than disease, may be important in 
adolescents not willing to accept that they have asthma 
(35). 
Education alone, however, is not enough to ensure 
compliance. Although steroid phobia may be overcome by 
educating the adolescent and parent to dispel any 
speculative beliefs, adolescents often do not understand 
what they are told about asthma (10). In a study of children 
aged 8-12 years with asthma receiving inhaled corticoster- 
oids and beta-agonists, both children and parents took part 
in an extensive asthma education programme and all 
demonstrated knowledge of the roles of beta-agonists and 
corticosteroids in their therapy (2.5). Subsequently, when 
self-reported compliance was compared with Chronolog- 
assessed compliance (an electronic device monitoring time 
and date of actuation), actual compliance was recorded as 
58% compared with the patient-reported level of 95%. The 
number of doses taken at correct intervals was also low at 
approximately 30%. More importantly, the consistency of 
diary entries detailing the child’s medication regimen 
reflected a clear understanding of the treatment schedule, 
although this did not correspond with actual use (25). 
Those children with severe asthma attacks that required 
additional treatment with oral corticosteroids were shown 
to be far less compliant than those who achieved adequate 
asthma control (median compliance of 14% and 68%, 
respectively) (25). 
Since the dosing regimen of therapy can have a 
significant impact on patient compliance, especially if it 
affects the lifestyle of the average adolescent, efforts to 
simplify the regimen are beneficial. Compliance with a 
variety of dosing regimens was assessed in children aged 
9-16 years with moderate-to-severe asthma, a factor likely 
to increase compliance. Small groups of children received 
inhaled corticosteroids at different prescribed dosing regi- 
mens. When inhaled medication was prescribed four times 
daily (n = 6), it was found to be taken as prescribed on 18% 
of days and, when administered three times daily (n = 3), on 
34% of days. Furthermore, reducing the dosing frequency 
to a twice-daily regimen (n= 5) resulted in a major 
improvement in compliance with medication then being 
taken as prescribed on 71% of days (24). 
Absolute percentage compliance values in this study need 
to be interpreted with caution, due to the small sample size 
and the relevance of these findings to patients who require 
regular therapy for mild-to-moderate rather than moderate- 
to-severe asthma. Nevertheless, it appears that reducing the 
dosing frequency of inhaled medication in adolescents with 
asthma is beneficial in terms of compliance. These findings 
are similar to those documented in a review of 26 
compliance studies in a variety of chronic conditions in 
adults, indicating that improvements in compliance are seen 
when the dosing regimen is reduced from a thrice- to twice- 
daily regimen. In this review there appears to be little 
difference in compliance between thrice- and four-times 
daily or between once- and twice-daily regimens (36). 
Many adolescents also have difficulties with the method 
of delivery of inhaled asthma therapy and, even in 
adolescents whose condition is stable on regular inhaled 
therapy, over 70% make one or more mistakes when using 
their metered dose inhaler. Furthermore, following inten- 
sive education, 14% of adolescents still fail to demonstrate 
an adequate inhaler technique (37). This suggests that for a 
small proportion of adolescents who do appear to comply 
well with their treatment, compliance may be unintention- 
ally reduced by the complexity of using an inhaled therapy. 
Although corticosteroids are the mainstay treatment in 
asthma, the introduction of new therapeutic options allows 
alternatives to be considered, which may help to improve 
compliance. 
Does oral therapy offer a useful 
alternative in treating adolescent 
asthma? 
Oral therapy avoids the obvious problems associated with 
inhaler technique and, in addition, non-steroidal oral 
therapy may reduce ‘steroid phobia’ which may create a 
barrier to achieving good compliance. For the clinician, an 
ideal alternative oral therapy for use in this age group 
should also provide similar control over asthma symptoms 
and exacerbations to low-dose inhaled corticosteroids, the 
mainstay of current asthma treatment. Non-steroidal oral 
asthma treatment options offer a potential solution to 
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improve asthma control by improving compliance in this 
difficult-to-treat patient population. 
Currently available oral anti-asthma treatments exclud- 
ing oral corticosteroids include theophylline, ketotifen-an 
anti-histamine with anti-anaphylactic properties-and the 
leukotriene modifiers, zileuton, zafirlukast, montelukast 
and pranlukast. 
THEOPHYLLINE 
Theophylline, available as both short- and long-acting 
preparations, is an oral bronchodilator that may also have 
anti-inflammatory effects (38-41). Theophylline has been 
shown to improve compliance compared with inhaled 
therapy in adolescents and may therefore be of benefit in 
this respect. In a retrospective review of medical records 
and pharmacy claims data from 276 patients with asthma 
who had concurrent prescriptions for theophylline and anti- 
inflammatory agents, data from 119 medical records were 
considered suitable for calculation of compliance rates. In 
this group, both adults and adolescents (aged 18-65 years 
and 12-17 years, respectively) complied significantly better 
with theophylline (especially the adolescents) than with 
inhaled corticosteroids or inhaled cromolyn (Fig. 1) (42). 
This study is severely limited because by measuring 
compliance using retrospective pharmacy claims data, it is 
assumed that the prescriptions were actually taken as 
dispensed-with the potential for over-estimation. Clinical 
trials using more direct measures of compliance may show 
80 - 
60 - P= 0.001 vs. 
theophylline 
more accurate values. Nevertheless, the study does allow 
some comparison between compliance for oral and inhaled 
medication. Limited efficacy, frequent side effects including 
nausea and headaches, and concerns regarding theophylline 
toxicity at higher doses have, however, discouraged its use 
as an alternative to low-dose inhaled steroids (43). 
KETOTIFEN 
Ketotifen is an oral HI-antagonist with inhibitory effects on 
the histamine-mediated allergic response. Anti-inflamma- 
tory properties have also been documented, although the 
mechanism of action in inflammation has not been clearly 
established (1,40). However, the benefits of treatment with 
ketotifen appear to be limited. In a long-term trial in 
children aged 2-6 years of age with chronic asthma 
receiving ketotifen, analyses of frequency of acute exacer- 
bations, symptoms, concomitant medication and parental 
and physician preference showed there were no significant 
differences between ketotifen and placebo groups (45). 
LEUKOTRIENE MODIFIERS 
Zileuton is a Slipoxygenase inhibitor that inhibits the 
synthesis of leukotrienes produced by the action of 
Uipoxygenase on arachidonic acid. These leukotrienes 
are produced from inflammatory cells such as mast 
cells, eosinophils and basophils, and are implicated 
in the pathogenesis of asthma, inducing smooth muscle 
P=O.O02vs. 
theophylline 
Oral Inhaled Inhaled cromolyn 
theophylline corticosteroids sodium 
FIG. 1. Drug-specific compliance with oral theophylline and inhaled anti-asthma medication in adults and adolescents with 
asthma. Compliance assessments were made after studying medical records and pharmacy claims data from 276 subjects. 
(Adapted and reproduced with permission from Kelloway et al. Arch Zntern Med 1994; 154:1349 [42]). n , adolescents 12-17 
yrs (n = 14); 8, adults 18-65 yrs (n = 105). 
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contraction, eosinophilic infiltration, vascular leakage and 
bronchoconstriction (4648). Zileuton can inhibit inflam- 
matory changes in the pathophysiology of asthma (49), and 
inhibits bronchospasm in patients with exercise-induced 
asthma (50). However, the need for a four-times daily 
dosing regimen, which is accompanied by elevated liver 
transaminase levels (51), is a major disadvantage of this 
drug, limiting its usefulness in adolescent asthma. 
The leukotriene receptor antagonists (LTRAs), zafirlu- 
kast and montelukast block the effects of leukotrienes at 
their receptor. These agents appear to prevent inflammation 
by inhibiting the activity of leukotrienes in target organs 
such as the lung. Both drugs are generally well tolerated 
and require less frequent dosing than zileuton as they are 
once- or twice-daily medications. In mild asthma, zafirlu- 
kast blocks both early and late responses to allergen 
challenge and also attenuates the associated increase in 
non-specific airway hyperreactivity (52). In addition, the 
LTRAs have been shown to reduce cellular infiltration and 
activation of inflammatory cells (53-55). 
The LTRAs are effective in reducing day- and night-time 
asthma symptoms, reducing rescue beta-agonist use and 
improving lung function in placebo-controlled trials (54 
57). There is also evidence that treatment with LTRAs 
reduces the frequency of asthma exacerbations in adults 
with mild-to-moderate and severe asthma (54, 5659). A 
recent meta-analysis of five 13-week trials with zafirlukast 
twice daily showed that the risk of requiring oral 
corticosteroids was reduced by approximately 50%, com- 
pared with placebo in patients with asthma receiving only 
beta-agonists as required (Fig. 2) (60). Montelukast has 
been shown to reduce the number of days with asthma 
Trial A 
(n = 89) 
h 
Trial B 
(n = 762) 
Trial C 
(n= 191) 
attacks by 31% compared with placebo in adults with 
chronic stable asthma, although the number of overall 
attacks was not significantly reduced (54). However, in a 
highly selected adult asthma patient population, montelu- 
kast was shown to be less effective than inhaled beclo- 
methasone diproprionate, although both treatments 
provided significant improvements over placebo (61). In 
patients who are likely to comply well with treatment, this 
study therefore supports the use of inhaled corticosteroids 
as the first-line treatment of choice in patients with mild 
persistent asthma. No double-blind efficacy comparisons 
have been performed with an LTRA versus a low-dose 
corticosteroid in symptomatic adolescent patients. How- 
ever, a 4-week randomized cross-over study in adolescents 
with stable asthma, aged 12-17 years, showed that 70% of 
adolescents preferred therapy with zafirlukast compared 
with only 27% preferring an inhaled corticosteroid 
delivered by a metered dose inhaler (37). This preference 
for oral asthma therapy with zafirlukast compared with 
inhaled beclomethasone was seen to a greater degree in 
adolescent asthmatics than adults (62). 
Twice-daily dosing of zafirlukast in adults has been 
shown to be associated with a high mean compliance rate of 
80% (monitored by a computerized capped bottle). Mean 
adherence to this oral therapy (total days with two tablets 
taken at the correct interval/total days on treatment) was 
64%, about twice the literature values for adherence with 
twice-daily inhaled asthma treatments, assessed using 
similar inhaler technology to the computerized capped 
bottle (23, 63). A factor possibly contributing to high 
compliance rates with the LTRAs may be that improve- 
ments are seen within days of starting treatment (54-57). 
n=692 
Trial D Trial E 
(n = 168) (n = 454) 
Meta analysis 
FIG. 2. Incidence and risk of asthma exacerbations requiring oral corticosteroid rescue therapy in 1664 patients treated with 
zafirlukast or matching placebo. Data for the meta-analysis were obtained from five 13-week placebo controlled trials 
performed in steroid na’ive patients (60). The risk of an asthma exacerbation requiring oral steroid treatment on zafirlukast 
20 mg b.d. was significantly less than that on placebo (Odds ratio = 0.58; 95% C.I. 0.340.97) 0, placebo b.d.; q d, zafirlukast 
20 mg b.d. P=O.Ol. 
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Non-compliance with inhaled corticosteroids in adolescents 
may in part result from no immediate positive effect on 
symptoms; compliance may therefore be poorer if patients 
perceive that therapy is having no immediate effect (43). 
The ability to participate in school sports and social 
activities may help to alleviate feelings of isolation 
prevalent among adolescents with asthma, and LTRAs 
have been shown to reduce the number of days absent from 
school by over 50% (64). An additional property of the 
LTRAs important in this age group is that they provide 
prolonged protection against bronchoconstriction induced 
by triggers such as exercise and cold air (43), reducing the 
need for more frequent and obstrusive inhaled medication 
to control or prevent asthma symptoms. A study in children 
aged 6-14 years showed that zafirlukast, administered 4 h 
before exercise reduced exercise-induced bronchoconstric- 
tion by at least 50% compared with placebo (65). 
Montelukast also inhibits exercise-induced bronchocon- 
striction in children with asthma and there is no evidence of 
tachyphylaxis when given for up to 12 weeks (66). 
LTRAs are an effective controller therapy in mild 
persistent asthma and may therefore provide a useful 
alternative controller treatment option in adolescents with 
mild persistent asthma unwilling or unable to take low-dose 
inhaled corticosteroids. 
Conclusion 
The transition from childhood into adulthood is a period of 
intense emotional and psychological change. For those with 
asthma, long-term treatment requirements pose an addi- 
tional burden. In particular, the highly visible nature of 
both asthma symptoms and the use of inhaled therapy have 
been shown to have an adverse impact on compliance with 
asthma therapy. Non-compliance with asthma therapy is 
particularly high in the adolescent age group and has 
implications for continuing high levels of morbidity and 
mortality. Improved patient management and education 
may improve compliance, but there remains a need for 
alternative treatment options in some patients. 
Oral therapy is simple to take and unobtrusive, factors 
which appear to result in increased preference for oral 
treatment in this age group. Whilst inhaled corticosteroids 
are likely to remain the first-line treatment of choice in 
adolescents with asthma, the benefits of oral agents support 
their use as alternative controller therapy. In particular, the 
increased compliance, rapid onset of action, good control 
over exacerbations and prolonged protection from exercise- 
induced asthma seen with the LTRAs make them a 
valuable alternative amongst currently available oral 
therapies. 
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